NEWS

JW Pharmaceutical agreed to collaboration with Deargen by using Deargen’s AI solution to develop new drugs

2022.10.06

Deargen announced on 6th that they agreed to collaborate with JW pharmaceutical to develop innovative new drugs via Deargen’s AI model. Read More

NEWS

Deargen begins full operation of iDear Center for AI-convergence drug development

2022.07.26

Deargen has completed the end-to-end AI drug development platform ‘DEARGEN iDeas” to serve as a high-quality data productino for advancing its platform. Read More

NEWS

[Interview] “Deargen enhances its pipeline to accelerate the AI-powered new drug development.”

2022.06.10

Inhwan Bae, CDO of Deargen, said through the iDear Center that Deargen will enhance the preclinical pipeline and be in full swing of innovative drug development. Read More

NEWS

“AI drug discovery companies should have technical skills and mid-to-long-term business model.”

2022.05.03

One of the most significant business models for AI drug development companies is collaborating with global companies.. Read More

NEWS

Deargen-NeogenTC, Announced a research collaboration on developing an AI platform for cancer immunotherapy.

2022.03.31

Deargen starts a research collaboration with NeogenTC to develop a TCR-T treatment prediction platform using Deargen’s sequence-based AI technology. Read More

NEWS

[Interview] “Dongtan RnD Center, iDear Center, will be an outpost of anti-cancer drugs”

2022.03.16

The first interview article on Kilsoo Kang, CEO of Deargen, after he successfully secured the SeriesB funding round. Read More

NEWS

Deargen, Accepted its research paper at AAAI Conference…“Introducing a new model for enhancement of estimation of certainty in new drug candidates.”

2022.03.16

Deargen presented a new AI technology on ‘enhanced model on estimating certainty in new drug candidates.’ Read More

NEWS

Sequence Based, AI-Driven Drug Discovery Company, Deargen Raises US$17 Million in SeriesB Financing Round to Accelerate In-House Pipeline

2022.03.02

Will establish a 2,600m2 AI convergence new drug development center (iDear Center) and accelerate internal new drug development Read More

NEWS

Deargen Announces Patent Application for a TNBC Target Novel Drug Candidate Using AI

2021.12.23

Deargen applied patent for a novel target compound candidate. Read More

NEWS

[Interview] Seven in-house pipeline promote a virtuous cycle of AI and new drug development

2021.11.19

Cooperation of CEO of Deargen U.S.A Bonggun Shin and CDO of Deargen Korea Read More

NEWS

Deargen-FarmHannong, a Co-Development Agreement to Develop AI-Powered Crop Protection Products

2021.08.05

Deargen expanding to crop protection product. Read More

NEWS

Deargen Signs Agreement with Sookmyung Women’s University for Licensing ‘NASH Biomarker’ Technologies

2021.07.27

Deargen secured the world’s largest level of NASH patients data. Read More

NEWS

Deargen-eFlask, signed a Co-development Agreement for AI-powered drug discovery

2021.07.01

Deargen collabotate with eflask to develop new drugs using artificial intelligence. Read More

NEWS

Deargen Adds Former Hanmi Pharmaceutical “Dr. Inhwan Bae” as CDO

2021.06.02

Deargen adds Dr. Bae In-hwan, who was the research director of Hanmi Pharmaceutical’s synthetic new drug team, as CDO. Read More

NEWS

Deargen, awarded the “Best AI Award” in the AI ​​Convergence Bio Health category

2021.05.24

Deargen received the “Best AI Award” in the AI Convergence Bio-Health category. Read More

NEWS

Kilsoo Kang, CEO of Deargen “Development of AI-specialized new drugs… Promotion of cooperation with global pharmaceutical companies”

2021.05.24

The first company that applied “Transformer” technology grafted onto biology. Read More

NEWS

Deargen-Samsung Medical Center signed a joint research agreement using ‘AI for The Development of Alzheimer Treatment’

2021.04.30

Deargen collaboration with Samsung Seoul Hospital, to discover new Alzheimer’s treatments using AI technology. Read More

NEWS

Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models

2021.04.09

At ACM CHIL 2021, Deargen presented study results on a model of simultaneously optimizing multiple properties of molecules. Read More

NEWS

AI startups team up with drugmakers for drug repurposing

2021.04.02

AI startups team up with drugmakers for drug repurposing Read More

NEWS

Deargen, Nominated as TOP10 for bioanalytical service company

2021.03.25

Deargen: Laveraging AI to Accelerate New Drug Development. Read More

NEWS

Deargen-Uppthera, co-development of Proteolytic drugs

2021.02.16

Deargen and Uptera selected two target proteins, including anti-cancer drugs, and signed a joint research contract. Read More

NEWS

AI-based Drug Discovery, What would be the limitation?

2021.02.05

AI-based Drug Discovery, What would be the limitation? Read More

NEWS

Handok- Signed a new drug development contract using artificial intelligence of Deargen

2021.01.06

HANDOK and Deargen will conduct joint researches on “oncology” and other diseases using DearDTI. Read More

NEWS

Daewoong Pharmaceutical subsidiary IN Therapeutics, now developing Hearing Loss Treatment

2020.11.17

Deargen collaboration with IN Therapeutics collaboration to develop a treatment for hearing loss. Read More

NEWS

[Press Release] Deargen- SK Chemicals- Joint research on new drug development using AI of Deargen

2020.11.08

SKChemical and Deargen will conduct joint researches on “drug repositioning” and “de novo drug design.”  Read More

NEWS

Deargen to attract 3 billion won for pre series A, recruited CBO Youngchul Bae

2020.11.03

Deargen to attract 3 billion won for pre series A, recruited CBO Youngchul Bae Read More

NEWS

Amyloidsolution, acquisition of AI biotech company Deargen, speeding up the development of new drug for AD

2020.11.03

Amyloidsolution, acquisition of Deargen, speeding up the development of new drug for AD. Read More

NEWS

[Press Release] Optipharm and Deargen start developing vaccine for liver cancer treatment using AI

2020.08.25

Optipharm and Deargen, Introduced AI to find antigens that cause immune responses to liver cancer cells. Read More

NEWS

[Event] DEARGEN, in ‘KOREA Pharm and Bio 2020’ Fair

2020.08.13

DEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Read More

NEWS

Five Companies Using AI to Fight Coronavirus

2020.03.23

Deep learning models predict old and new drugs that might successfully treat COVID-19. Read More

NEWS

Deargen Predicted Potential Antivirals for The Novel Coronavirus Infection using AI

2020.02.07

Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the AI technology. Read More

TECH REVIEW

MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds

2020.02.05

Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at AACR2020. Read More

PROJECTS

First-in Class Drug Targeting DDT2 (Code Name) Transcription Factor for Primary Cancers

2019.09.03

We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS. Read More

TECH REVIEW

A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.

2019.08.14

Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI. Read More

NEWS

[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.

2019.08.12

“All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”. Read More

PROJECTS

Treatment of Sarcopenia using Small Molecules

2019.08.05

Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules. Read More

PROJECTS

Undruggable to Degradable with AI

2019.08.05

PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein. Read More

PROJECTS

Colorectal Cancer, MERTK, and Small molecular

2019.08.05

The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors. Read More

PROJECTS

ALS (Lou Gehrig), a Challenge to Radical Cure

2019.08.05

ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig. Read More

NEWS

[Press Release] Deargen, Signed a Strategic Technology Agreement with Uppthera for Discovering PROTAC Drug Candidates using AI.

2019.08.02

Deargen Inc. signed a strategic technology partnership agreement with Uppthera Inc. Read More

TECH REVIEW

Prediction of origin of cancer by deep-learning analysis using pan-cancer transcriptome

2019.07.22

We introduce DEARGEN’s research results on the model that predicts the primary cancer sites through the gene expression profile. Read More

TECH REVIEW

CWx (Cascaded Wx): Technology for Prognosis Biomarker Discovery

2019.07.19

Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis. Read More

TECH REVIEW

WX: Technology for Novel Biomarker Discovery

2019.07.19

Deargen has announced research results on an AI technology Wx that can discover novel biomarkers. Read More

NEWS

Deargen, Selected for the TIPS Program with Genomic Data Analysis Service

2018.11.15

Deargen was selected for the TIPS program, so it will receive a total of $600,000 in R & D expenses from the operator Medytox Venture Investment. Read More

NEWS

Genomic Data Analysis Platform ‘DearTRANS’ Beta Service Launch

2018.07.06

Deargen launches a beta service of ‘DearTRANS’ that is a cloud-based genomic big data analysis platform. Read More

NEWS

The Challenge to Conquer Cancer, Prognostic Prediction Analysis of Lung Cancer Using AI

2017.04.17

Deargen has been selected for the 2017 National Program for Cancer Control. Read More

NEWS

Deargen was selected as Top Performers of the NCI-CPTAC DREAM Challenge

2017.01.20

Deargen was selected as a Top Performer of the NCI-CPTAC DREAM Proteogenomics Computational Challenges. Read More

NEWS

Deargen, Won at ILSVRC 2016 (ImageNet Large Scale Visual Recognition Challenge)

2016.12.23

Deargen was voted in the top 10 in the world at the ‘ImageNet Large Scale Visual Recognition Challenge (ILSVRC) 2016’. Read More